Over the past three months, 12 analysts have provided diverse ratings for Tenet Healthcare (NYSE: THC), with 6 bullish and 6 somewhat bullish assessments. The average price target has increased to $259.25, up 5.28% from the previous average of $246.25, with a high estimate of $288.00 and a low of $229.00. The article also highlights Tenet Healthcare’s strong financial health, including impressive net margin, return on equity, and return on assets, despite a high debt-to-equity ratio.
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
The Analyst Verdict: Tenet Healthcare In The Eyes Of 12 Experts
Over the past three months, 12 analysts have provided diverse ratings for Tenet Healthcare (NYSE: THC), with 6 bullish and 6 somewhat bullish assessments. The average price target has increased to $259.25, up 5.28% from the previous average of $246.25, with a high estimate of $288.00 and a low of $229.00. The article also highlights Tenet Healthcare’s strong financial health, including impressive net margin, return on equity, and return on assets, despite a high debt-to-equity ratio.